Understand · Treat · Recover

Chronic Lymphocytic Leukemia (CLL)

CLL often follows a slow course. For some people, careful observation is the correct initial treatment strategy.

For patients and families. This education does not replace an individual treatment plan. Do not start, stop or change medicines without the treating team.

Chapter 7 of 20 · B · Leukemia

Diagnosis and staging

CLL involves a clone of mature B lymphocytes. A CBC and blood flow cytometry commonly establish the diagnosis; the number and persistence of clonal cells and the clinical setting matter. Small lymphocytic lymphoma (SLL) is closely related but presents mainly in tissues. A small B-cell clone without features of CLL may be called monoclonal B-cell lymphocytosis. Rai or Binet staging uses features such as nodes, spleen and low blood counts; it is not the same as solid-tumor TNM staging.

Why watch and wait can be best

In asymptomatic early disease without treatment indications, starting medicine immediately has not generally improved outcomes enough to justify its risks. Active observation includes scheduled appointments, examination, blood counts and symptom review. It is not neglect. A high lymphocyte count by itself is usually not a reason to start treatment. The speed of change, symptoms and causes of low blood counts must be considered.

When treatment becomes necessary

  • Progressive marrow failure causing clinically important anemia or low platelets attributable to CLL.
  • Progressively enlarging or symptomatic nodes or spleen.
  • Significant disease-related symptoms, after infection and other causes are excluded.
  • Certain rapidly progressive blood-count changes or autoimmune blood-cell destruction that is not controlled with appropriate therapy.

Genetic assessment before choosing treatment

Testing for deletion 17p and TP53 mutation is important before treatment; these are related but not identical tests. IGHV mutation status helps characterize disease biology. TP53-related assessment is often repeated before later treatment because the cancer can evolve. These are usually tests of cancer cells, not a diagnosis of inherited risk. Discuss the results and their effect on drug selection, rather than simply asking whether a panel is “positive”.

Targeted treatment and its trade-offs

Modern options often include a BTK inhibitor such as acalabrutinib or zanubrutinib, or a time-limited venetoclax-based combination, often with an anti-CD20 antibody. Some approaches continue until intolerance or progression; others have a planned end. BTK inhibitors can cause bleeding, blood-pressure and heart-rhythm problems. Venetoclax requires staged initiation and tumor-lysis precautions. Drug interactions, renal function, affordability and the ability to attend monitoring visits affect the choice. Conventional chemoimmunotherapy has a smaller role in modern practice.

Monitoring beyond the leukemia count

CLL can weaken immunity even without treatment. Discuss vaccination timing, infections and age-appropriate cancer screening. Report rapidly enlarging nodes, new marked systemic symptoms or a sudden clinical change; occasionally CLL transforms into a faster lymphoma, which generally needs biopsy confirmation. Most CLL is managed for long-term control rather than a promised cure. Early supportive and palliative care can help symptoms whenever needed.

Take-home message

Ask why treatment is or is not needed now, and what specific changes should trigger review.

Common questions

Does observation mean the cancer is being ignored?

No. It is a planned strategy with clear review intervals and triggers for treatment.

Can infection occur while counts look high?

Yes. A high lymphocyte count does not mean the immune system is functioning normally.

Sources and further reading

Cancer Aware supports patients and families worldwide. Treatment availability, approvals and care pathways vary by country; discuss local options with your healthcare team.